Prepare for your visit
Beth A Carella
Pediatric Hematology-Oncology · Baltimore, MD · NPI 1992931182
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$770.96
in general payments reported to CMS, 2019-2025
Who reported paying
General payments only, top 5 by amount.
- Merck Sharp & Dohme LLC $623.10
- Pfizer INC. $83.61
- Duchesnay USA Incorporated $27.43
- Novartis Pharmaceuticals Corporation $22.69
- Uswm, LLC $14.13
Drugs and devices associated with these payments
Oxbryta Siklos Promacta Iwilfin
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Beth Carella listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/3589353/beth-a-carella